Skip to main content
SpringerLink
Log in

Use of Infliximab within 3 Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn’s Patients

  • ssat plenary presentation
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Background

Few studies have evaluated preoperative infliximab use and postoperative outcomes in Crohn’s patients. Our aim was to evaluate 30-day postoperative outcomes for Crohn’s patients treated with infliximab within 3 months prior to ileocolonic resection.

Methods

The study is a retrospective evaluation of data for patients undergoing ileocolonic resection after 1998 from a prospective Crohn’s disease database. Patient characteristics and 30-day complications were compared for patients treated with infliximab within 3 months before surgery and an infliximab naïve group. The infliximab group was also compared with non-infliximab patients undergoing ileocolonic surgery before 1998.

Results

Sixty of 389 Crohn’s patients undergoing ileocolonic resection received infliximab. The infliximab and non-infliximab groups had similar characteristics, preoperative risk factors, and surgical procedure. However, steroid use was higher (p < 0.05) in the non-infliximab group while concurrent immunosuppressive use was higher (p < 0.001) in the infliximab group. Multivariate analysis showed infliximab use to be associated with 30-day postoperative readmission (p = 0.045), sepsis (p = 0.027), and intraabdominal abscess (p = 0.005). The presence of diverting stoma (n = 17) in the infliximab group was associated with lower risk of sepsis (0% vs. 27.9%, p = 0.013). Similar results were noted when the infliximab group was compared to the pre-infliximab patients.

Conclusions

Infliximab use within 3 months before surgery is associated with increased postoperative sepsis, abscess, and readmissions in Crohn’s patients. Diverting stoma may protect against these complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. van Hogezand RA. Medical management of patients with difficult-to-treat inflammatory bowel disease. Neth J Med. 1994;45(2):55–59.

    PubMed  Google Scholar 

  2. Rasenack J, Kreisel W. Conservative therapy of ulcerative colitis and Crohn disease. Fortschr Med. 1991;109(11):245–247.

    PubMed  CAS  Google Scholar 

  3. Hanauer SB. Medical therapy for Crohn’s disease. Curr Opin Gastroenterol. 1999;15(4):308–314. doi:10.1097/00001574-199907000-00006

    Article  PubMed  CAS  Google Scholar 

  4. Hanauer SB. Clinical perspectives in Crohn’s disease. Turning traditional treatment strategies on their heads: current evidence for “step-up” versus “top-down”. Rev Gastroenterol Disord. 2007;7(Suppl 2):S17–22.

    PubMed  Google Scholar 

  5. Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up? Curr Opin Gastroenterol. 2007;23(4):395–399. doi:10.1097/MOG.0b013e32815b601b

    Article  PubMed  Google Scholar 

  6. Frikker MJ, Segall MM. The resectional reoperation rate for Crohn’s disease in a general community hospital. Dis Colon Rectum. 1983;26(5):305–309. doi:10.1007/BF02561704

    Article  PubMed  CAS  Google Scholar 

  7. Polle SW, Slors JF, Weverling GJ, Gouma DJ, Hommes DW, Bemelman WA. Recurrence after segmental resection for colonic Crohn’s disease. Br J Surg. 2005;92(9):1143–1149. doi:10.1002/bjs.5050

    Article  PubMed  CAS  Google Scholar 

  8. Sachar DB. Maintenance strategies in Crohn’s disease. Hospital Practice (1995) 1996;31(1):99–106.

    CAS  Google Scholar 

  9. Murray JJ, Schoetz DJ Jr, Nugent FW, Coller JA, Veidenheimer MC. Surgical management of Crohn’s disease involving the duodenum. Am J Surg. 1984;147(1):58–65. doi:10.1016/0002-9610(84)90035-7

    Article  PubMed  CAS  Google Scholar 

  10. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–1035. doi:10.1056/NEJM199710093371502

    Article  PubMed  CAS  Google Scholar 

  11. Kornbluth A. Infliximab approved for use in Crohn’s disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis. 1998;4(4):328–329. doi:10.1002/ibd.3780040415

    Article  PubMed  CAS  Google Scholar 

  12. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF. et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549. doi:10.1016/S0140-6736(02)08512-4

    Article  PubMed  CAS  Google Scholar 

  13. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol. 2003;98(10):2232–2238. doi:10.1111/j.1572-0241.2003.07674.x

    Article  PubMed  CAS  Google Scholar 

  14. Andus T, Stange EF, Hoffler D, Keller-Stanislawski B. Suspected cases of severe side effects after infliximab (Remicade) in Germany. Med Klin (Munich). 2003;98(8):429–436. doi:10.1007/s00063-003-1282-9

    Article  Google Scholar 

  15. Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5(6):729–735. doi:10.1016/j.cgh.2007.02.016

    Article  PubMed  Google Scholar 

  16. Byrne CM, Solomon MJ, Young JM, Selby W, Harrison JD. Patient preferences between surgical and medical treatment in Crohn’s disease. Dis Colon Rectum. 2007;50(5):586–597. doi:10.1007/s10350-006-0847-0

    Article  PubMed  Google Scholar 

  17. Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents-a guide for GPs. Aust Fam Physician. 2007;36(12):1035–1038.

    PubMed  Google Scholar 

  18. Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS. et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204(5):956–962. discussion 962–953. doi:10.1016/j.jamcollsurg.2006.12.044

    Article  PubMed  Google Scholar 

  19. Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008;51(8):1202–1207.

    Article  PubMed  CAS  Google Scholar 

  20. Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T. et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99(5):878–883. doi:10.1111/j.1572-0241.2004.04148.x

    Article  PubMed  CAS  Google Scholar 

  21. Marchal L, D’Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M. et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther. 2004;19(7):749–754. doi:10.1111/j.1365-2036.2004.01904.x

    Article  PubMed  CAS  Google Scholar 

  22. Cornillie F, Shealy D, D’Haens G, Geboes K, Van Assche G, Ceuppens J. et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther. 2001;15(4):463–473. doi:10.1046/j.1365-2036.2001.00956.x

    Article  PubMed  CAS  Google Scholar 

  23. Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn’s disease. Expert Opin Drug Saf. 2006;5(1):9–16. doi:10.1517/14740338.5.1.9

    Article  PubMed  CAS  Google Scholar 

  24. Reddy JG, Loftus EV Jr. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006;35(4):837–855. doi:10.1016/j.gtc.2006.09.008

    Article  PubMed  Google Scholar 

  25. Weston-Petrides GK, Lovegrove RE, Tilney HS, Heriot AG, Nicholls RJ, Mortensen NJ. et al. Comparison of outcomes after restorative proctocolectomy with or without defunctioning ileostomy. Arch Surg. 2008;143(4):406–412. doi:10.1001/archsurg.143.4.406

    Article  PubMed  Google Scholar 

  26. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005;34(6):819–836. doi:10.1016/j.semarthrit.2004.11.006

    Article  PubMed  CAS  Google Scholar 

  27. Kalkay MN, Cordoba I, Plevy D. The nonreflux determinant of esophagitis. Am J Gastroenterol. 1975;63(2):135–146.

    PubMed  CAS  Google Scholar 

  28. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D. et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J Immunol. 1997;159(12):6276–6282.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Sincere Appreciation to:

The Pharmacy Department at CCF for providing medication lists.

Digestive Disease Center Database staffs and coordinators for their impute on the Crohn’s Database; secretaries of Dr. Fazio, Dr. Church, Dr. Shen, and Dr. Kiran for coordinating appointments.

Author information

Authors and Affiliations

  1. The Cleveland Clinic Foundation, Cleveland, OH, USA

    Kweku A. Appau, Victor W. Fazio, Bo Shen, James M. Church, Bret Lashner, Feza Remzi, Aaron Brzezinski, Scott A. Strong, Jeffrey Hammel & Ravi P. Kiran

Authors
  1. Kweku A. Appau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor W. Fazio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bo Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James M. Church
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bret Lashner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Feza Remzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aaron Brzezinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Scott A. Strong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jeffrey Hammel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ravi P. Kiran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kweku A. Appau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Appau, K.A., Fazio, V.W., Shen, B. et al. Use of Infliximab within 3 Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn’s Patients. J Gastrointest Surg 12, 1738–1744 (2008). https://doi.org/10.1007/s11605-008-0646-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-008-0646-0

Keywords

Search

Navigation